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Abstract
T-cell acute lymphoblastic leukemia (T-ALL) is a high-risk type of blood-cell cancer. We describe
the improvement of a candidate therapeutic virus for virotherapy of leukemic cells. Virotherapy is
based on the exclusive replication of a virus in leukemic cells, leading to the selective removal of
these malignant cells. To improve the safety of such a virus, we constructed an HIV-1 variant that
replicates exclusively in the presence of the nontoxic effector doxycycline (dox). This was achieved
by replacement of the viral TAR-Tat system for transcriptional activation by the Escherichia coli-
derived Tet system for inducible gene expression. This HIV-rtTA virus replicates in a strictly dox-
dependent manner. In this virus, additional deletions and/or inactivating mutations were introduced
in the genes for accessory proteins. These proteins are essential for virus replication in
untransformed cells, but dispensable in leukemic T cells. These minimized HIV-rtTA variants
contain up to 7 deletions/inactivating mutations (TAR, Tat, vif, vpR, vpU, nef and U3) and replicate
efficiently in the leukemic SupT1 T cell line, but do not replicate in normal peripheral blood
mononuclear cells. These virus variants are also able to efficiently remove leukemic cells from a
mixed culture with untransformed cells. The therapeutic viruses use CD4 and CXCR4 for cell
entry and could potentially be used against CXCR4 expressing malignancies such as T-
lymphoblastic leukemia/lymphoma, NK leukemia and some myeloid leukemias.
Background
Virotherapy has been proposed as a novel therapeutic
means against certain cancers and is currently being eval-
uated in clinical trials [1-3]. This novel strategy is based on
the selective replication of viruses in specific target cells to
efficiently remove these cells from the patient. Initial suc-
cesses have been reported in the treatment of head and
neck cancers using an engineered adenovirus [4-7], but
doubts remain about the absolute restriction of virus rep-
lication in cancer cells [8]. In an ideal setting, the thera-
peutic virus should replicate exclusively in malignant
cells. A large number of target cells will enable a fast
spreading viral infection at the start of therapy. Conse-
quently, the number of target cells will rapidly decline and
result in a concurrent reduction of the virus population. It
may be necessary to modify therapeutic viruses to increase
their replication specificity and/or to modulate their
cytopathogenicity. For instance, cytotoxic genes may be
incorporated into the viral genome or virus spread may be
improved by inclusion of genes encoding fusogenic pro-
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teins [9]. Experiments have thus far focused on virother-
apy of solid tumors. Therapeutic viruses have been
described based on adenovirus [10,11], herpes simplex
virus [12], Newcastle disease virus, poliovirus, vesicular
stomatitis virus, measles virus and reovirus [1-3]. No ther-
apeutic viruses have been described that replicate in lym-
phoid-leukemic cells.
We explored the possibility to use HIV-1 derived viruses,
which specifically target T-lymphocytes, as therapeutic
virus for leukemia and recently reported the proof of prin-
ciple with a minimal HIV-1 variant [13]. Our approach
was based on the observation that several accessory pro-
teins are not needed for HIV-1 replication in transformed
T-cell lines, yet are important for virus replication in pri-
mary cells. A minimized derivative of HIV-1 with five gene
deletions (vif, vpR, vpU, nef and U3) was demonstrated to
replicate in several leukemic T cell lines, but not in normal
peripheral blood mononuclear cells (PBMC).
Obvious safety concerns remain for the development of
therapeutic viruses based on the human pathogen HIV-1.
One of the major concerns is the high mutation and
recombination rate of HIV-1 that allows the generation of
escape variants over time. For instance, virus evolution
frequently leads to the appearance of drug-resistant
mutants in patients on antiviral therapy. It could be
argued that repair of gene deletions would be impossible,
but one cannot exclude alternative viral strategies to
improve its fitness or replication capacity. Such an indi-
rect escape strategy has been reported for a HIV-1 vaccine
candidate with three gene deletions [14]. Gradual
improvement of viral fitness has also been reported for
persons infected with a nef-deleted virus variant, coincid-
ing with AIDS disease progression in some of these
patients [15]. We therefore designed a method to gain full
control over viral replication. For this, we combined the
minimal HIV-1 strategy with that of the HIV-rtTA virus
[16], a vaccine candidate that was engineered to replicate
exclusively in the presence of the nontoxic effector dox.
The latter was achieved by replacement of the viral TAR-
Tat system for transcriptional activation by the Escherichia
coli-derived Tet system for inducible gene expression [17].
HIV-rtTA lacks several protein coding genes and non-cod-
ing structural elements and replicates in a strictly dox-
dependent manner, and has been proposed as a safe form
of an attenuated vaccine strain because its replication can
be turned on and off at will.
We designed two molecular clones based on HIV-rtTA.
rtTAΔ6A carries four deletions (vif, vpR, nef and U3) and
two genome regions with inactivating mutations (TAR,
vpU). rtTAΔ6B has five deletions (vif, vpR, vpU, nef and
U3) and inactivating mutations in TAR. The efficacy of
these therapeutic viruses was tested by replication studies
in the leukemic T-cell line SupT1 and PBMC. Both viruses
replicate efficiently and in a dox-dependent manner in
SupT1 cells, resulting in rapid cell killing. In contrast,
these viruses are unable to replicate in PBMC. Further-
more, the rtTAΔ6A and rtTAΔ6B viruses were able to selec-
tively infect and remove the SupT1 cells from a mixed
culture with PBMC.
Results
Design of dox-inducible mini-HIV variants
We recently reported the development of a mini-HIV-1
variant for virotherapy of T-ALL [13]. This minimized
HIV-1 derivative carries five deletions (vif, vpR, vpU, nef
and U3). The deleted genes/motifs contribute to virus rep-
lication in untransformed cells, but are dispensable for
replication in leukemic T-cells. To obtain control over
virus replication, we now combined the mini-HIV
approach with the dox-dependent HIV-rtTA concept
[16,18]. The nef gene in HIV-rtTA is replaced by the gene
encoding the rtTA protein (Fig. 1). In the presence of dox,
the transcriptional activator rtTA protein binds to tetO
binding sites that were introduced in the U3 domain of
the LTR promoter (Fig. 1, black box). Tat-mediated tran-
scriptional activation is abrogated by an inactivating
mutation in the tat gene (Tyr26Ala)[19,20] and multiple
inactivating mutations in the TAR hairpin (indicated by
crosses in Fig. 1) [16]. HIV-rtTA also carries a deletion of a
large upstream part of the U3 domain [21] and thus rep-
resents a Δ4 HIV-rtTA genome (Fig. 1, ΔTAR, tat, nef, U3).
HIV-rtTA was further minimized by deletion of genes
encoding the accessory proteins Vif and VpR. Addition-
ally, the vpU gene was inactivated in rtTAΔ6A (Fig. 1) by
mutation of the startcodon (AUG to AUA) and in rtTAΔ6B
by gene deletion. Due to the vpU-cloning procedure, the
wild type tat gene was restored. These minimized rtTAΔ6A
and rtTAΔ6B variants express the basic set of HIV-1 pro-
teins (gag, pol, env), the essential Rev and Tat proteins,
but lack the accessory proteins Vif, VpR, VpU and Nef. The
RNA genome of rtTAΔ6B is 8,872 nt compared to 9,229 nt
for full length HIV-1 LAI and 9,607 nt for the parental
HIV-rtTA virus.
Replication characteristics of the mini-rtTA viruses
Viral gene expression and production of virus particles
was tested by transfection of the mini-rtTA plasmids in
C33A cells. These cells lack the CD4 receptor and are thus
not susceptible for multiple rounds of HIV-1 replication.
We measured no difference in virus production of the
mini-rtTA viruses compared with the original HIV-rtTA
construct (Fig. 2). All constructs are fully dependent on
dox for gene expression. These results demonstrate that
none of the deleted/mutated genes/motifs play an impor-
tant role in viral gene expression (transcription, splicing,
and translation) and the assembly of new virions. Virus
production of all dox-dependent rtTA viruses is somewhatRetrovirology 2006, 3:64 http://www.retrovirology.com/content/3/1/64
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lower than that of the wild type LAI virus, consistent with
our previous studies [16,22].
The virus stocks produced in C33A cells were used to
infect the HIV-susceptible leukemic T-cell line SupT1.
Virus replication was followed by sampling of the culture
supernatant and measurement of the CA-p24 concentra-
tion (Fig. 3, left panel). Surprisingly, replication of the
minimized rtTAΔ6A and rtTAΔ6B variants is significantly
faster than that of the parental HIV-rtTA virus and even
faster than the wild type LAI virus. Similar results were
obtained in multiple replication assays that were initiated
either by virus infection or by transfection of the molecu-
lar clones (results not shown). Direct virus competition
assays confirmed this ranking order, with rtTAΔ6A being
slightly more fit than rtTAΔ6B, and both much more fit
than HIV-rtTA (results not shown). This surprise finding
will be dealt with in detail later in this paper. As expected,
virus replication is fully dependent on dox addition.
The T-cell cultures were also analyzed for the cell killing
capacity of these viruses. A time-limited FACS analysis was
used to determine the relative number of live cells in the
infected cultures and a mock-infected SupT1 culture as the
control. The cell killing capacity was determined by divid-
ing the number of cells in the infected culture by the
number of cells in the control culture (Fig. 3, right panel).
The LAI virus and the different HIV-rtTA variants are able
to kill all SupT1 cells. The cell killing kinetics correlate
nicely with the replication capacity of the respective
viruses. There was no decrease in the number of live cells
when the HIV-rtTA virus was tested without dox, confirm-
ing that the increase in cell death is the result of active
virus replication.
Overview of the minimal HIV-rtTA molecular clones Figure 1
Overview of the minimal HIV-rtTA molecular clones. Schematic overview of the different molecular clones used in this 
study. The position of the various deletions and a summary of the inactivated (-) or deleted () viral genes/motifs is provided. 
See the Materials and Methods section for details on the construction. See also Fig. 7 for further details.
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We tried to set up experiments with patient derived pri-
mary leukemic T-cells but the high death rate of these cells
in in vitro culture experiments (without any virus) pre-
vented any significant conclusions to be reached about
virus-induced cell killing (results not shown).
Switching virus replication on and off at will
Dox-regulation should allow strict control over replica-
tion of the therapeutic viruses. To demonstrate the regula-
tory possibilities of this system, we followed several
rtTAΔ6A  cultures with different dox regimens, ranging
from no to continuous dox treatment. We also tested
delayed dox addition and dox-withdrawal near the peak
of infection. Virus infections were started with dox (Fig. 4,
upper left panel) or without dox (Fig. 4, lower left panel)
and virus production was followed by measurement of
the CA-p24 concentration in the supernatant. After nine
days, the cultures were split and either continued with the
same treatment (Fig. 4, left panels) or switched from dox
to no dox (Fig. 4, upper right panel) or vice versa (Fig. 4,
lower right panel). The results show that virus replication
is completely controllable by dox. In the cultures with dox
a productive infection is started that can be turned off by
withdrawal of dox. In the cultures that were started with-
out dox, a single round of infection takes place that leads
to the establishment of an integrated but silent provirus,
Replication and cell killing capacity of dox-inducible viruses in SupT1 cells Figure 3
Replication and cell killing capacity of dox-inducible viruses in SupT1 cells. (Left) Virus replication of LAI (), HIV-
rtTA (▲), HIV-rtTAΔ6A (❍), HIV-rtTAΔ6B () and HIV-rtTA without dox (×) was determined by measuring of the superna-
tant CA-p24 concentration after infection with virus (20 ng CA-p24) in a 5 mL SupT1 culture. (Right) The number of cells in 
each culture was determined by a 30 sec time limit FACS analysis. The cell killing capacity of the viruses was determined as the 
ratio of SupT1 cells present in the infected culture versus the uninfected control culture.
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which can subsequently be activated by the addition of
dox.
Replication characteristics of the HIV-rtTA viruses in 
PBMC
The different HIV-rtTA viruses were further analyzed by
testing their replication capacity on PBMC (Fig. 5, left
panel). Killing of the CD4+ target cells was plotted as the
CD4+/CD8+ ratio relative to that of the control culture
without dox (Fig. 5, right panel). The wild type HIV-1 LAI
isolate replicates efficiently, resulting in a high peak of
CA-p24 production and complete removal of the CD4+
cells from the PBMC culture within 5 days. Due to the
removal of target cells, the CA-p24 concentration reaches
a maximum at 3 days post infection and subsequently lev-
els off. The parental HIV-rtTA virus replicates slowly, but
eventually reaches CA-p24 values similar to that of the wt
virus. In this culture, a gradual reduction in CD4+ cells is
scored, but HIV-rtTA replication is completely dependent
on dox addition. No production of CA-p24 was measured
in the PBMC cultures infected with the minimized
rtTAΔ6A and rtTAΔ6B variants, and no significant reduc-
tion in the CD4+/CD8+ ratio was observed. Thus, these
viruses are unable to cause a spreading infection in PBMC.
Dox regulated replication of the mini-rtTA virus rtTAΔ6A Figure 4
Dox regulated replication of the mini-rtTA virus rtTAΔ6A. SupT1 cells were infected with rtTAΔ6A virus (1 ng CA-
p24). The culture was split and the cells were cultured with dox (upper panels) or without (lower panels). Virus replication was 
monitored by CA-p24 Elisa on the culture supernatant. At day 9 post infection, both cultures were washed and each culture 
split into one culture with dox (left panels) and one without (right panels). Filled triangles indicate cultures without dox and 
open triangles indicate cultures with 1000 ng/mL dox.
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Extending the time for replication by feeding these cul-
tures with fresh PBMC did also not result in a spreading
infection.
It cannot be excluded that the rtTAΔ6A and rtTAΔ6B viruses
replicate at an extremely low level, and thus stay below the
CA-p24 detection limit. To test for this, we used a very sen-
sitive SupT1-based rescue assay to screen for viable virus
in the PBMC cultures. PBMC were harvested at day 13,
washed and subsequently co-cultured with SupT1 cells.
Virus replication is readily observed in the control co-cul-
tures derived from the LAI and HIV-rtTA infections. No
virus could be detected in the cultures derived from the
rtTAΔ6A or rtTAΔ6B infections, even with 1000-fold more
input sample compared to the LAI or HIV-rtTA samples.
Selective removal of leukemic T-cells from a mixed culture
In a virotherapy setting, the blood of a patient will contain
a mixture of leukemic and untransformed cells. The viral
therapeutic agent should selectively replicate and kill the
leukemic target cells without affecting the untransformed
cells. To mimic this situation in our in vitro culture system,
we started co-cultures of the SupT1 cell line and PBMC.
These cells can easily be distinguished by FACS analysis
using the CD4 and CD8 surface markers. SupT1 cells are
double positive T-cells (CD4+CD8+), whereas PBMC con-
tain a mixture of single positive CD4+CD8- and CD4-
CD8+ cells (Fig. 6, left). A PBMC-SupT1 culture was split
in five samples. These cultures were infected with an equal
amount of HIV-rtTA, rtTAΔ6A or rtTAΔ6B virus. The two
remaining cultures were used for a mock infection and a
control rtTAΔ6A infection without dox. The cell composi-
tion was followed over time by FACS analysis, showing
the more rapid proliferation of leukemic SupT1 cells ver-
sus PBMC in the uninfected control (mock, upper panels).
The same result was obtained for the rtTAΔ6A control
without dox (rtTAΔ6A-dox, lower panels). In contrast, the
SupT1 cells are selectively depleted in 8 days from the cul-
tures containing rtTAΔ6A or rtTAΔ6B virus with dox. In
agreement with the slower replication kinetics of HIV-rtTA
in SupT1 cells (Fig. 3), SupT1-depletion is delayed for this
virus. These results indicate that it is possible to selectively
remove leukemic T-cells from a mixture with untrans-
formed cells by the use of a dox-controlled mini-HIV-1
variant.
Effects of different Tat proteins on the replication of the 
dox-inducible mini-rtTA viruses
We constructed two dox-regulated viruses that specifically
target leukemic T cells. A surprising finding was that these
viruses, with many deletions (Δ6), replicated much better
in SupT1 cells than the parental construct HIV-rtTA (Fig.
3). In the construction of rtTAΔ6A and rtTAΔ6B, the wild-
type tat open reading frame is restored when compared to
the rtTA virus that carries the Y26A inactivating Tat muta-
tion. Although Tat-mediated transcriptional activation is
not needed for replication of the dox-controlled virus, it is
possible that Tat restoration enhances virus replication by
other means, which may explain the enhanced replication
of rtTAΔ6 variants.
Replication and cell killing capacity of dox inducible viruses in PBMC Figure 5
Replication and cell killing capacity of dox inducible viruses in PBMC. (Left) Virus replication of LAI (), HIV-rtTA 
(▲), rtTAΔ6A (❍), rtTAΔ6B () and rtTA without dox (×) was determined by monitoring the supernatant CA-p24 concentra-
tion after virus infection (40 ng CA-p24) in a 5 mL PBMC culture. (Right) The CD4+ and CD8+ cell populations in the 
infected cultures and an uninfected control culture were quantified by a 30 sec time limit FACS analysis and the CD4/CD8 
ratio was calculated. The figure shows the CD4/CD8 ratio in the infections normalized for the control uninfected PBMC cul-
ture.
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To test this hypothesis, the Y26A mutation was reintro-
duced in the rtTAΔ6A and rtTAΔ6B background, yielding
the rtTAΔ7A and rtTAΔ7B viruses, respectively. For compar-
ison, the mutant tat gene (Y26A) in the HIV-rtTA virus was
also replaced by the wild-type tat gene from the LAI iso-
late, yielding rtTAΔ3 (LAI), or the tat gene from the NL4-
3 isolate, yielding rtTAΔ3 (NL4-3). This set of viruses was
used to infect SupT1 cells to test their replication capacity
(Fig. 8). Comparison of the replication capacity of
rtTAΔ6A versus rtTAΔ7A, rtTAΔ6B versus rtTAΔ7B (Fig. 8,
left) and rtTAΔ3 (LAI) versus HIV-rtTA (Fig. 8, right) dem-
onstrate that the Y26A Tat mutation causes a small
decrease in replication. Thus, a wild-type tat gene
improves replication. The introduction of the NL4-3 tat
gene in HIV-rtTA, however, improved replication much
more than introduction of the tat gene of the LAI isolate
(Fig. 8, left panel, compare rtTAΔ3 (NL4-3) with HIV-rtTA
and rtTAΔ3 (LAI)). In fact, the rtTAΔ3 (NL4-3) variant rep-
licated consistently better that the wild type LAI virus.
Similar results were obtained in repeated infections and in
replication studies that were initiated by DNA transfection
(results not shown).
Discussion
We describe the development of therapeutic viruses based
on HIV-1 for virotherapy against T-ALL. We combined
mini-HIV-1 variants [13] that lack several accessory pro-
teins with the dox-controllable HIV-rtTA virus approach
[16]. One molecular clone, rtTAΔ6A, has four deletions
(vif, vpR, nef and U3) and two motifs with inactivating
mutations (TAR and vpU). The molecular clone rtTAΔ6B is
similar, but the vpU gene is deleted instead of having the
inactivating mutation. These mini-rtTA viruses replicate
efficiently in leukemic T-cell lines and virus replication
results in cell death. These viruses do not replicate in
PBMC, even in co-cultures with susceptible SupT1 cells
that continuously produce new infectious virus particles
(Fig. 6). The results are summarized in Table 1. Most
importantly, virus replication is strictly dox-dependent.
The viral Vif protein counters the potent antiviral activity
of APOBEC3G in some cells including PBMC [reviewed in
[23]], and the absence of Vif may therefore be the main
contributor to the replication defect in primary cells. Nev-
ertheless, the other accessory proteins (vpR, vpU and Nef)
Selective SupT1 killing in SupT1/PBMC co-cultures by mini-rtTA viruses Figure 6
Selective SupT1 killing in SupT1/PBMC co-cultures by mini-rtTA viruses. Infections were started with virus corre-
sponding to 40 ng CA-p24 or mock infected. The FACS dot plot of the initial PBMC + SupT1 cell mixture is in the lower left 
corner, and the separate cultures are shown above. The gates for CD4+ PBMC (blue), SupT1 (red) and CD8+ PBMC (green) 
are indicated. The composition of the PBMC + SupT1 culture was followed over time upon infection with the indicated viruses.
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also have important roles in vivo [24-26] and in vitro
[13,27-29]. The presence of multiple gene deletions will
not only increase safety of the therapeutic virus, but may
also provide synergistic effects. For instance, it was
recently demonstrated that the combined elimination of
the vif and vpR genes, unlike the individual mutants,
renders the virus incapable of causing cell death and G2
cell cycle arrest [30].
A surprising finding is that removal of the genes encoding
the accessory proteins Vif, VpR and VpU appeared to have
a positive effect in the context of the dox-controlled HIV-
rtTA virus, whereas the same deletions have a negative
impact when introduced into the wild-type HIV-1 isolate
[13]. This observation enabled us to make HIV-1 variants
that replicate extremely fast in leukemic cells, yet are fully
replication-impaired in primary cells. This result, com-
bined with the strict dox-regulation, suggests to us that a
safe therapeutic use of these virus variants is feasible. In a
therapeutic setting, the minimized virus can be used to
target the leukemic cells in the presence of dox. This will
result in a self-limiting viral infection since the target cells
are killed by the virus. Withdrawal of dox provides an
additional safety feature to block ongoing replication after
the leukemic cells are removed. It may be possible to add
therapeutic short interfering RNAs (siRNAs) to this viral
vector system [31]. We plan to set up a T-ALL model in
severe combined immunodeficiency (SCID) mice to test
the capacity of these therapeutic viruses to selectively
remove leukemic cells in vivo.
HIV-rtTA was originally designed as a novel attenuated
virus vaccine candidate. To minimize the possibility of
reversion to normal TAR-Tat regulated transactivation,
inactivating mutations were made in both the TAR hairpin
and the Tat protein (Y26A). In our minimized Δ6 deletion
variants, a wild type NL4-3 tat gene was introduced due to
the cloning procedure. Restoration of a wild type Tat func-
tion could explain the observed fast replication kinetics of
these viruses. However, reintroduction of the Y26A muta-
tion in these viruses (rtTAΔ7A and rtTAΔ7B) caused only a
small decrease in replication capacity, which is consistent
with previous results [16]. The TAR hairpin in these con-
structs is inactivated by multiple point mutations, which
are sufficient as individual point mutation to block Tat-
mediated transcription [16,32-34] and virus replication
[35]. Restoration of the normal Tat-TAR transcription axis
is therefore an unlikely scenario in the dox-dependent
virus. Thus, the absence of the Y26A mutation does not
provide an explanation for the improved replication, but
the results demonstrate that the Y26A mutation, apart
from abolishing Tat-TAR mediated transcription, has an
additional (small) negative effect on the replication of
HIV-rtTA.
Another possible explanation for the improved replica-
tion of the mini-HIV-rtTAs is provided by inspection of
the sizes of these viral genomes. The RNA genome of the
wild-type HIV-1 LAI isolate is 9,229 nt, but the HIV-rtTA
genome is extended to 9,607 nt due to the insertion of the
rtTA gene and tetO DNA binding sites. The latter genome
size may be sub-optimal for replication, e.g. due to
restricted RNA packaging in virion particles, and removal
of the vif-vpR-vpU genes may thus be beneficial in this
context. Deletion of these genes reduces the RNA genome
to 8989 for rtTAΔ6A and to 8872 for rtTAΔ6B. One would
nevertheless expect a reduction of viral fitness due to
removal of three accessory genes, unless these viral-pro-
tein functions do not add significantly to virus replication
in T cell lines. In fact, we consistantly measured that the
rtTAΔ6 variants replicate significantly faster than the wild-
type virus in T-cell lines, perhaps indicating that some of
the accessory HIV-1 genes have a negative impaction on
virus replication in these leukemic cells. Consistent with
this idea is the frequent selection of inactivation muta-
tions in these open reading frames upon prolonged cul-
turing in T cell lines. Alternatively, these viral functions
may have lost significance in the context HIV-rtTA, in
which Tat-TAR mediated transcription is taken over by the
rtTA-tetO elements. For instance, VpR has been reported
to have a transcriptional component [36], and this tran-
scriptional contribution may be less important in the
HIV-rtTA context.
Another explanation comes from the comparison of the
control viruses rtTAΔ3 (NL4-3) and rtTAΔ3 (LAI) that
have the same gene deletions, yet a different tat gene. The
introduction of the NL4-3 tat gene improved virus replica-
tion significantly more than insertion of the LAI tat gene.
In fact, the replication of rtTAΔ3 (NL4-3) is similar to that
of rtTAΔ6A and rtTAΔ6B. Thus, the presence of a fragment
encoding the NL4-3 tat gene is the decisive determinant
for the improved replication of rtTAΔ6A, rtTAΔ6B  and
rtTAΔ3 (NL4-3). As discussed above, this is not due to the
Y26A mutation, which has a similar small negative effect
in both sequence contexts (LAI and NL4-3). Furthermore,
this effect appears to be specific for the HIV-rtTA virus
since replication of the mini-HIV-1 virus, which has a wild
type NL4-3 tat gene, is impaired [13].
Table 1: Virus replication and cell killing capacity
SupT1 PBMC
virus replication cell killing replication CD4+ killing
L A I+ ++ ++ + + +
HIV-rtTA + ++ + ±
rtTAΔ6A ++ ++ - -
rtTAΔ6B ++ ++ - -Retrovirology 2006, 3:64 http://www.retrovirology.com/content/3/1/64
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The differences between the fast replicating virus rtTAΔ3
(NL4-3) and the slow replicating rtTAΔ3 (LAI) are located
exclusively in the 350 nt tat fragment. This fragment
encodes the first exon of the tat gene, the overlapping first
exon of the rev gene and part of the open reading frames
for vpU and Env. The sequence differences result in six
amino acid substitutions in Tat (Fig. 7B, N24T in the
Cysteine-rich domain, M39T in the core domain and
A58P, H59P, N61G and A67V in the C-terminal domain).
In addition, these sequence differences also change the rev
gene (Fig. 7C, E11D, I13L, R14K T15A and L21F). Further-
more, there are two substitutions in the vpU gene (I5Q
and V60I). We can exclude some of these differences to
play a role in this phenotype by comparison with the effi-
cient replicating rtTAΔ7A  and rtTAΔ7B  viruses. These
viruses lack the vpU gene and have the LAI-specific Threo-
nine at position 24 in Tat, indicating that these motifs are
not responsible for the improved phenotype. Thus, the
differences are caused by one or more of the remaining
substitutions in the core and/or C-terminal domain of Tat
or the overlapping Rev protein. Recently, it was reported
that tat genes from different HIV-1 subtypes differentially
regulate gene expression [37]. Our results demonstrate
that sequence variation in this genome segment can have
a profound effect on replication even when derived from
the same subtype B.
Materials and methods
DNA-constructs
Full-length molecular HIV-1 clones are based on an
improved variant of the dox-inducible HIV-1 variant
described previously [38]. We first deleted the accessory
proteins vif and vpR in this HIV-rtTA virus. Plasmid
pDR2483 [39], which contains the 5' genome of the HIV-
1 isolate NL4-3 with deletions in the genes encoding the
vif and vpR proteins, was used as template in a PCR reac-
tion with primers RJ001 (5' GGG CCT TAT CGA TTC CAT
CTA 3') and 6 N (5'CTT CCT GCC ATA GGA GAT GCC
TAA G 3'). The resulting PCR fragment was cut with ClaI
and EcoR1 and ligated with a 9644 bp BclI-EcoR1 HIV-rtTA
vector fragment and a 1816 bp BclI-ClaI fragment from
pLAI-001 [13] to generate the subclone rtTAΔvifΔvpR. We
Overview of the different tat constructs Figure 7
Overview of the different tat constructs. (A) The position of the various deletions and mutations, and a summery of the 
inactivated (-) or deleted () viral genes is shown. See the Materials and Methods section for construction details. (B) 
Sequence alignment of the different tat genes. The position of the Y26A mutation is indicated in bold. (C) Sequence alignment 
of the corresponding part of the rev gene. The rev startcodon overlaps the tat codon for Y47.
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noticed a vpU startcodon inactivation (AUG to AUA) in
one of the evolution cultures [13]. Proviral DNA was PCR
amplified from total cellular DNA of this culture with the
primers Pol5'FM (5'TGG AAA GGA CCA GCA AAG CTC
CTC TGG AAA GGT 3') and WS3 (5'TAG AAT TCA AAC
TAG GGT ATT TGA CTA AT). The same PCR was per-
formed on DNA from a vpU-deletion construct
[pDR2484, [39]]. The PCR fragments were cut with EcoRI
and NdeI and ligated with a 2086 bp wild type (wt)t rtTA
BamHI-NdeI fragment and the vector rtTAΔvifΔvpR cut
with EcoRI and BamHI. The resulting molecular clones
(Fig. 1) were named rtTAΔ6A (vpU startcodon inactiva-
tion) and rtTAΔ6B (vpU deletion).
As part of the vpU inactivation strategy, the Y26A inacti-
vating mutation in the tat gene of HIV-rtTA is replaced by
the wt tat gene of the NL4-3 isolate (first exon). The Y26A
mutation was cloned back into the rtTAΔ6A and rtTAΔ6B
molecular clones as follows. A PCR was done with HIV-
rtTA as template and primers Pol5'FM and RJ036 (5'CTT
TTG TCA TGA AAC AAA CTT GGC A 3'). The latter primer
introduces a BspHI site that is also present in the wt NL4-
3 sequence. The PCR product was digested with EcoRI and
BspHI and used in a triple ligation with the 9028 bp EcoRI-
BamHI vector and either the 2545 bp BspHI-BamHI frag-
ment of rtTAΔ6A or the 2428 bp BspHI-BamHI fragment of
rtTAΔ6B. For comparison, we also introduced the LAI and
NL4-3 tat gene into the HIV-rtTA background. For NL4-3,
this was done in a triple ligation with the rtTA vector cut
with SphI and Asp718 I, the 4378 bp SalI-SpHI rtTA frag-
ment and the 558 bp SalI-Asp718 I fragment of pDR2480
[39]. For LAI this was done by ligation of the 9646 bp
NcoI-BamHI digested HIV-rtTA vector with the 2811 bp
NcoI-BamHI fragment of LAI.
All constructs were verified by restriction enzyme diges-
tion and BigDye terminator sequencing (Applied Biosys-
tems, Foster City, CA) with appropriate primers on an
automatic sequencer (Applied Biosystems DNA sequencer
377). Plasmid DNA isolation was done with the Qiagen
Plasmid isolation kit according to the manufacturers' pro-
tocol (Qiagen, Chatsworth, CA).
CA-p24 levels
Culture supernatant was heat inactivated at 56°C for 30
min in the presence of 0.05% Empigen-BB (Calbiochem,
La Jolla, USA). CA-p24 concentration was determined by
a twin-site ELISA with D7320 (Biochrom, Berlin, Ger-
many) as the capture antibody and alkaline phosphatase-
conjugated anti-p24 monoclonal antibody (EH12-AP) as
the detection antibody. Detection was done with the
lumiphos plus system (Lumigen, Michigan, USA) in a
LUMIstar Galaxy (BMG labtechnologies, Offenburg, Ger-
many) luminescence reader. Recombinant CA-p24
expressed in a baculovirus system was used as the refer-
ence standard.
Effects of different Tat proteins on the replication of the dox inducible rtTA viruses Figure 8
Effects of different Tat proteins on the replication of the dox inducible rtTA viruses. Virus replication was followed 
by measuring of the supernatant CA-p24 concentration after virus infection (20 ng CA-p24) in a 5 mL culture. (Left) Replica-
tion of the rtTAΔ6A (●), rtTAΔ7A (❍), rtTAΔ6B (), rtTAΔ7B () and LAI () viruses in Sup T1 cells. (Right) Replication of 
the rtTAΔ3 (LAI, +), rtTAΔ3 (NL4-3, X), HIV-rtTA (▲) and LAI () viruses in Sup T1 cells.
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Cells and viruses
C33A cervix carcinoma cells [ATCC HTB31, [40]] were
grown as a monolayer in Dulbecco's minimal essential
medium supplemented with 10% (v/v) fetal calf serum
(FCS), 100 U/mL penicillin, 100 μg/mL streptomycin, 20
mM glucose and minimal essential medium nonessential
amino acids at 37°C and 5% CO2. The cells were trans-
fected by the calcium phosphate method as described pre-
viously [41].
The human T lymphocyte cell line SupT1 [ATCC CRL-
1942, [42]] was cultured in RPMI 1640 (Gibco BRL,
Gaithersburg, MD) supplemented with 10% (v/v) FCS,
100 U/mL penicillin, and 100 μg/mL streptomycin at
37°C and in 5% CO2. Transfections were carried out by
electroporation as described [43] using a BioRad Gene
Pulser II (BioRad, Hercules, CA). Infection with C33A
produced virus stocks was performed with the indicated
amount of virus.
PBMC were isolated from different healthy donors, each
batch consists of a mixture of four different donors. PBMC
were grown as the SupT1 cells, but with the addition of
100 U/mL human IL2 after an initial PHA (5 μg/mL) stim-
ulation for 2 days. Infections were performed with C33A
produced virus stocks with the indicated amount of virus.
Virus competition assay
Virus competition experiments were done as described
previously [44]. Competitions were initiated with C33A
produced virus stocks. Each competition was done with
virus corresponding to 6 ng virus with starting ratios of 5
to 1, 1 to 1 and 1 to 5. The competition was repeated with
independent virus stocks.
Virus rescue assay
Low-level replication in PBMC was analyzed with a virus
rescue assay. At day 13 post infection of PBMC, the cells
from 1 mL culture were collected (4 min 4000 RPM,
eppendorf centrifuge), washed once with 1 mL PBS to
remove any input virus and resuspended in medium. A
dilution series (1, 10×, 100×, 1000×, 10.000×) was made
and each sample mixed with one million SupT1 cells. The
cultures were maintained for four weeks, regularly split
and inspected for virus replication by CA-p24 Elisa on the
culture supernatant and visual inspection for syncytia for-
mation.
Fluorescence-activated cell sorting analysis
Flow cytometry was performed with RPE-conjugated
mouse monoclonal anti-human CD4 (clone MT310,
Dako, Glostrup, Denmark) and FITC-conjugated mouse
monoclonal anti-human CD8 (clone DK25, Dako). Cells
from a 1 mL culture sample were collected (4 min 4000
RPM, eppendorf centrifuge), incubated with a mixture of
both monoclonal antibodies in fluorescence-activated cell
sorting (FACS) buffer (PBS with 2% FCS) for 30 min at
room temperature and washed with 800 μL FACS buffer.
The cells were subsequently collected (4 min 4000 RPM,
eppendorf centrifuge) and resuspended in 20 μL of 4%
paraformaldehyde. After 5-minute incubation at room
temperature, 750 μL FACS buffer was added and the sus-
pension analyzed on a FACScalibur flow cytometer with
CellQuest Pro software (BD biosciences, San Jose, CA).
The machine was set for a 30-sec collection time. Cell pop-
ulations were defined based on forward/sideward scatter-
ing and isotype controls were used to set markers. For
mixed SupT1 plus PBMC cultures, the gates for PBMC
(CD4+CD8- and CD4-CD8+) and SupT1 (CD4+, CD8+)
were set using a separate control culture.
Mixed culture SupT1/PBMC infection
Freshly isolated PBMC were stimulated for 2 days with
PHA (5 μg/mL), washed twice with medium and mixed
with SupT1 cells. The cell mixture was analyzed by FACS
staining for CD4 and CD8 as described above. The culture
was divided into equal 10 mL samples, containing
approximately 1 million PBMC and 2 million SupT1 cells,
which were infected with different virus variants (input 40
ng CA-p24). Daily samples were taken for CA-p24 Elisa
and anti-CD4/CD8 FACS analysis.
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